In: In vivo CAR-T
What this is
- How it works
- Reprograms the patient's own immune T cells, inside the body, to hunt one kind of cell, such as cancerous B cells. Standard CAR-T does this in a lab.In vivo CD19 CAR, circular RNA in targeted lipid nanoparticles
- How it’s given
- “Targeted lipid nanoparticle (tLNP)-delivered circular ribonucleic acid (circRNA) encoding an anti-human CD19 chimeric antigen receptor (CAR)”In the company’s words, NCT07765966 on ClinicalTrials.gov
- Tested for
- Immune Thrombocytopenia (ITP), Relapsed/Refractory B Cell-Mediated Autoimmune Diseases
- Main trialPhase 1
- “The Phase 1 is to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of RXIM002 in patients with relapsed or refractory autoimmune cytopenias.”In the company’s words, NCT07765966 on ClinicalTrials.gov
Coming up2
- 19 Dec 2027Early Phase 1 trial completes · ClinicalTrials.gov
- 30 Jun 2028Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Not yet recruiting | 30 Jun 2028 | Phase 1 Dose Escalation Study of RXIM002 in Autoimmune Cytopenias | |
| Early Phase 1Recruiting | 19 Dec 2027 | Safety and Efficacy Study of RXIM002 in Severe, Relapsed or Refractory Autoimmune Diseases |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 16 Nov 2026 · EU trials register (CTIS) updated 16 Nov 2026 · openFDA updated 13 Nov 2026